The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

FDA approval was based on the AcT noninferiority trial that found tenecteplase (at 0.25 mg/kg) to be at least on par with alteplase for safety and efficacy in acute ischemic stroke in Canadians ...

For patients with large vessel occlusion presenting between 4.5 and 24 hours, intra-arterial tenecteplase after successful thrombectomy results in improved likelihood of excellent outcome (modified ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a ...

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...

The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...

Ascension Wisconsin recently honored Racine paramedics and the Ascension All Saints Hospital Emergency Department for their ...